Matti Adam
Latest contributions
Transcatheter mitral valve replacement - LIVE case
20 May 2026 – From EuroPCR 2026
A 65‑year‑old woman with obesity (BMI 38.7), prior cardiac surgery (CABG to OM and LAD in 2012), and chronic kidney disease presented with symptomatic severe mitral regurgitation (Carpentier type III: type IIIa due to calcification and type IIIb post‑MI) with moderately reduced LVEF (45%).
A transcatheter mitral...
Secondary mitral regurgitation: not all patients are the same
20 May 2026 – From EuroPCR 2026
Examining secondary mitral regurgitation, this session differentiates patient phenotypes and discusses the application of updated guideline recommendations. It offers practical guidance on selecting the appropriate device tailored to individual patient characteristics, supported by detailed case studies.
From referral to discharge: European consensus on the TAVI care pathway
19 May 2026 – From EuroPCR 2026
Across Europe, TAVI programmes are under increasing pressure from rising demand, capacity limits and referral barriers. This EuroPCR 2026 session presents the European consensus on the TAVI care pathway and explores how data-driven, standardised approaches can optimise the patient journey from referral to discharge.
Bringing together clinicians,...
What criteria for the index TAVI procedure in younger and lower risk patients?
21 May 2026 – From EuroPCR 2026
In this discussion, Matti Adam and Didier Tchétché explore how to optimise the index TAVI procedure in younger, low-risk patients, emphasising the importance of achieving excellent hemodynamic results, ensuring long-term durability, maintaining coronary access, and planning for potential redo procedures. Patient anatomy and high-quality imaging remain...
How to plan and perform TAVI in more challenging tricuspid AS anatomies?
12 May 2026
Watch this replay to learn how to anticipate anatomical challenges and optimize TAVI planning in complex tricuspid AS cases.
From assessment to strategy: choosing the optimal treatment for severe tricuspid regurgitation
12 May 2026
Severe tricuspid regurgitation is no longer a bystander disease.
In this elderly patient with persistent symptoms despite optimised medical therapy, a comprehensive multimodality assessment becomes key to determining the right timing and the most appropriate transcatheter strategy.
Author
Author
High calcium, high stakes: managing severe AS with complex multivessel disease
12 May 2026
A 69-year-old woman with severe symptomatic aortic stenosis (NYHA III) and complex comorbidities, including three-vessel coronary artery disease, advanced COPD, and peripheral artery disease, presents with progressive dyspnoea despite recent PCI. How would you treat this patient?
Author
Author
Author
How to perform ELASTA-Clip: lacerating M-TEER devices to enable TMVR
09 Mar 2026
Recurrent mitral regurgitation after M-TEER can create a challenging scenario. Discover the ELASTA-Clip technique and its key steps to enable TMVR!
Author
Author
A new era for aortic regurgitation: how new guidelines and dedicated devices for AR will redefine treatment
18 Nov 2025 – From PCR London Valves 2025
This session examines the evolving treatment landscape for aortic regurgitation (AR) in light of new ESC guidelines and dedicated devices such as the JenaValve Trilogy System. It provides an in-depth look at refined diagnosis, optimized treatment strategies, and presents real-world data and clinical cases that highlight...
TAVI for pure aortic regurgitation: different animal, different challenges, different approaches
17 Nov 2025 – From PCR London Valves 2025
This session delves into the unique anatomical and pathophysiological challenges posed by pure aortic regurgitation and their impact on treatment strategies. It reviews clinical outcomes with established and new transcatheter devices, and presents emerging technologies that promise to advance therapeutic options for this distinct patient population.
From pivotal trial to real-world impact: shaping TR treatment today with the EVOQUE system
16 Nov 2025 – From PCR London Valves 2025
Rebecca Hahn, Varius Dannenberg and Matti Adam discuss the updated ESC/EACTS guidelines for tricuspid regurgitation, which upgrade transcatheter tricuspid interventions to a IIa recommendation. Evidence from the TRILUMINATE and TRISCEND II trials shows improved quality of life and reduced heart failure hospitalisations, especially in patients with...
New approaches in aortic regurgitation
16 Nov 2025 – From PCR London Valves 2025
Explore new diagnostic and therapeutic approaches for managing aortic regurgitation. This session covers imaging modalities, guideline-directed patient selection, current transcatheter treatment techniques, and emerging TAVI technologies designed specifically for non-calcific aortic valve pathology.
Transcatheter tricuspid valve replacement: who to treat and how to implement into my practice
12 Nov 2025
In this on-demand webinar, F. Praz, P. Lurz, M. Adam, and T. Patterson explore TTVR, sharing key insights and the latest clinical evidence supporting TTVR.
Leaflet modification to prevent coronary obstruction during TAVI
22 May 2025 – From EuroPCR 2025
This session addresses advanced leaflet modification techniques to prevent coronary obstruction during TAVI. Learn from detailed cases involving valve-in-valve interventions, treatment of failed stentless valves, homograft management, and dedicated devices for leaflet modification prior to valve-in-valve and valve-in-valve-in-valve procedures.
TAVI for aortic regurgitation off label
22 May 2025 – From EuroPCR 2025
Explore off-label applications of TAVI for aortic regurgitation in complex clinical scenarios. Topics include TAV-in-SAV with Trilogy valve for severe regurgitation, challenges of transcatheter prosthesis in pure aortic regurgitation, management of surgical valve perforations, and treatment strategies in post-surgical anatomies including degenerative homografts and aortic dissection.
Emerging indications for TAVI in 2025
22 May 2025 – From EuroPCR 2025
Prepare for emerging TAVI indications anticipated in 2025. This session reviews clinical cases including asymptomatic severe aortic stenosis, moderate aortic stenosis with heart failure, and severe aortic regurgitation. It discusses supporting evidence from clinical trials, evolving transcatheter technologies, and practical treatment approaches for these novel indications.
TAVI in difficult scenarios: bicuspid anatomy and pure aortic regurgitation
22 May 2025 – From EuroPCR 2025
Address challenging TAVI scenarios involving bicuspid anatomy and pure aortic regurgitation with insights from international experiences. This session compares treatment options in China and Germany, explores anatomical and disease differences, and reviews various TAVI devices through detailed case presentations and expert commentary.
Future-proof your TAVI programme: increased need to enhance pathway efficiencies
21 May 2025 – From EuroPCR 2025
Explore evolving guidelines, demographic changes, and new data shaping lifetime TAVI management. Learn precision strategies to optimise patient outcomes before, during, and after TAVI, including post-procedural care and PCI with the Evolut FX+ valve. Discover practical approaches to boost hospital efficiency and embrace innovative technologies that...
New iterations of self expendable valves - LIVE case
25 Nov 2024 – From PCR London Valves 2024
Watch a LIVE case followed by a recorded case on enhanced TAVI:
- An 80-year-old female with severe symptomatic aortic stenosis, a complete right bundle branch block (RBB), and preserved LV function. The operators implanted a 25 mm ACURATE Prime valve following predilation with a 22 mm balloon....
TAVI for pure aortic regurgitation - LIVE case
25 Nov 2024 – From PCR London Valves 2024
Watch a LIVE case followed by a recorded case on aortic regurgitation:
- An 86-year-old male with a history of stroke and prostate cancer presenting acute heart failure due to severe pure aortic regurgitation and LV dysfunction (EF 39%). A 27 mm JenaValve Trilogy prosthesis was implanted without...
A window into the future - Expanding horizons for patients with long life expectancy with the Evolut FX + TAVI system
25 Nov 2024 – From PCR London Valves 2024
Gain insights into the key considerations when performing TAVI in patients with long life expectancy, including long-term outcomes, valve durability, and the feasibility of future redo-TAVI. Discover the latest data on TAVI in women and patients with small annulus anatomy, as well as a live case...
Mitral valve replacement devices and techniques
16 May 2024 – From EuroPCR 2024
This session comprises selected EuroPCR 2024 Clinical Case submissions focused on mitral valve replacement devices and techniques. It covers various case presentations and discussions, including the treatment of mitral regurgitation with atrial fixation TMVR, mitral valve-in-valve with a novel device, transcatheter treatment of a structurally degenerated...
Innovation and strategies in TAVI: design, data and directions for clinical practice
15 May 2024 – From EuroPCR 2024
Watch this session to explore considerations for TAVI implantation in small annuli, gain insights into future lifetime management, learn about the benefits of FX technology and clinical evidence beyond small annuli, and witness a live case procedure showcasing the innovation of FX plus. This session is...
TAVI in challenging anatomies
14 May 2024 – From EuroPCR 2024
Explore the complexities of TAVI in patients with intricate aortic stenosis: learn the critical role of detailed CT imaging and meticulous pre-procedural planning, and find out how to customize valve selection and implantation techniques to match unique patient anatomies, such as highly calcified tricuspid valves, low...
Late-breaking trials: TAVI head-to-head
14 May 2024 – From EuroPCR 2024
This session presents the latest findings from several late-breaking trials comparing different transcatheter aortic valve implantation (TAVI) approaches. Topics include outcomes in women with small aortic annuli, the comparison of percutaneous versus surgical treatment for patients with aortic stenosis and coronary disease, the impact of valve...
Valve in valve - TAV in TAV - Part 2
21 Nov 2023 – From PCR London Valves 2023
Join us for this session, where complex cases shed light on the evolving landscape of valve-in-valve interventions: delve into the efficacy of THV-in-THV for addressing supra-skirtal leakage accompanied by intravascular hemolysis, learn more about the challenges of TAVI-in-TAVI with the deployment of SAPIEN3 Ultra in a...
TAVI in complex scenarios - Bicuspid aortic valve disease - putting it all together
20 Nov 2023 – From PCR London Valves 2023
After an overview of what is currently known about TAVI in bicuspid aortic valves, follow the analysis of a real-life clinical case, and get tips on how to perform TAVI in a bicuspid aortic valve in 3 different ways: with a self-expanding supra-annular valve, using a...
Rapid-fire - Nightmares in the cathlab - Part 2
20 Nov 2023 – From PCR London Valves 2023
TAVI in complex scenarios
19 Nov 2023 – From PCR London Valves 2023
What do we mean by "complex scenarios"? When zero-contrast TAVI implantation becomes a good alternative in kidney disease, when TAVI is implanted in a patient with mechanical mitral valve, or when TAVI is implanted in very large annulus with subannular aneurysm, for example!
